ZYN-001
ZYN-001, also known as Δ 9 -tetrahydrocannabinol D -glyceric acid ester, is a cannabinoid which was under development for the treatment of cancer pain, neuropathic pain, fibromyalgia, and Tourette's syndrome but was never marketed.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ZYN-001, also known as Δ 9 -tetrahydrocannabinol D -glyceric acid ester, is a cannabinoid which was under development for the treatment of cancer pain, neuropathic pain, fibromyalgia, and Tourette's syndrome but was never marketed. It was formulated as a transdermal patch.
The drug is a synthetic prodrug of Δ 9 -tetrahydrocannabinol (Δ 9 -THC) and acts as a cannabinoid CB 1 and CB 2 receptor agonist. ZYN-001 was under development by Zynerba Pharmaceuticals. It reached phase 1 clinical trials prior to the discontinuation of its development in 2018.
The drug was discontinued after it failed to attain target THC blood levels of 5 to 15 ng/mL in a phase 1 trial.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1333568621 under CC BY-SA 4.0; modifications have been made.